Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF)

G. Ferrara (Stockholm, Sweden), K. Bartley (South San Francisco, CA, United States of America), A. Levine (Solna, Sweden), L. Arnheim-Dahlstrom (Solna, Sweden), K. Kirchgaessler (Basel, Switzerland), R. Linder (Solna, Sweden), C. Janson (Uppsala, Sweden), C. Sköld (Stockholm, Sweden)

Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Session: The world of idiopathic pulmonary fibrosis (IPF): global registries
Session type: Poster Discussion
Number: 2202
Disease area: Interstitial lung diseases

Congress or journal article abstractE-posterSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Ferrara (Stockholm, Sweden), K. Bartley (South San Francisco, CA, United States of America), A. Levine (Solna, Sweden), L. Arnheim-Dahlstrom (Solna, Sweden), K. Kirchgaessler (Basel, Switzerland), R. Linder (Solna, Sweden), C. Janson (Uppsala, Sweden), C. Sköld (Stockholm, Sweden). Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF). 2202

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: